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Abstract
Kv1.3 is a voltage gated potassium channel that has been implicated in pathophysiology of multiple sclerosis (MS). In the 
present study we investigated temporal and cellular expression pattern of this channel in the lumbar part of spinal cords 
of animals with experimental autoimmune encephalomyelitis (EAE), animal model of MS. EAE was actively induced in 
female Dark Agouti rats. Expression of Kv1.3 was analyzed at different time points of disease progression, at the onset, 
peak and end of EAE. We here show that Kv1.3 increased by several folds at the peak of EAE at both gene and protein level. 
Double immunofluorescence analyses demonstrated localization of Kv1.3 on activated microglia, macrophages, and reac-
tive astrocytes around inflammatory lesions. In vitro experiments showed that pharmacological block of Kv1.3 in activated 
astrocytes suppresses the expression of proinflammatory mediators, suggesting a role of this channel in inflammation. Our 
results support the hypothesis that Kv1.3 may be a therapeutic target of interest for MS and add astrocytes to the list of cells 
whose activation would be suppressed by inhibiting Kv1.3 in inflammatory conditions.
Keywords Experimental autoimmune encephalomyelitis · Voltage gated potassium channel Kv1.3 · Astrocytes · 
Agitoxin-2 · Neuroinflammation
Introduction
Multiple sclerosis (MS) is an autoimmune neurodegen-
erative disease characterized by chronic inflammation and 
demyelination of the central nervous system (CNS). Dis-
ease is initiated by infiltration of autoreactive immune cells 
into the CNS, which propel inflammatory reaction against 
myelinated axons [1], followed by activation of resident 
microglial cells which drive further pathology, ultimately 
leading to degenerative lesions of the brain and spinal 
cord and loss of neurological functions [2–4]. Many recent 
reports suggest that microglia are not responsible just for 
the recurring neuroinflammation in the later phases of the 
disease, but they even may participate in the initiation of the 
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neuroinflammatory cascade [2]. The suggestion is corrobo-
rated by evidence that activation of microglia precedes the 
infiltration of peripheral macrophages and the appearance 
of clinical symptoms of the illness [5]. Moreover, pharma-
cological blockade of microgliosis prevents development 
of neurological symptoms in experimental autoimmune 
encephalomyelitis (EAE), the most commonly used animal 
model of MS [6].
Astrocytes are the second resident effector cells with 
dual roles in MS [7, 8]. Activated astrocytes withdraw their 
perivascular end feet, which increases the permeability of 
the blood–brain barrier (BBB) and facilitates the entry of 
T cells into the CNS [8]. These cells release chemokines 
which attract immune cells to the sites of tissue damage 
and produce cytotoxic factors, such as reactive nitrogen and 
oxygen species, thus acting as mediators of inflammation. 
Reactive astrocytes also develop hypertrophied processes 
which impede remyelination and axon regeneration [9]. On 
the other hand, astrocytes can support anti-inflammatory 
response and myelin repair by limiting the spread of reactive 
immune cells and by releasing anti-inflammatory cytokines 
and chemokines which stimulate migration and differentia-
tion of oligodendrocyte progenitor cells [7].
The autoimmune-mediated demyelination in MS/EAE, 
causes alterations in expression and function of several ion 
channels in axonal membranes, which leads to an increased 
excitability and augmented intracellular  Ca2+ concentra-
tions, and results in mitochondrial dysfunction and neuronal 
cell death [10]. Ion channels, including voltage-gated potas-
sium channel Kv1.3, control membrane potential and con-
tribute to several immune and effector cell functions [11]. 
The Kv1.3 channels open with membrane depolarization 
and allow outward potassium currents, which counteract 
the potential change [12]. This channel is best known for its 
roles in immune cells like T [13–15] and B cells [16, 17], 
macrophages [18, 19] and dendritic cells [20, 21]. In the 
CNS, the channel is also present in microglia [22–24] and 
select population of central and peripheral neurons [25, 26].
A number of clinical and experimental studies show pre-
dominant expression of Kv1.3 at subpopulations of infil-
trated T cells and macrophages [15]. The upregulation is 
particularly prominent at activated macrophages [27, 28] 
and subpopulations of Th17 and myelin-reactive effector 
memory T cells  (TEM), which show several-fold increase in 
number of Kv1.3 channel molecules in respect to the resting 
state [13]. In addition, Kv1.3 channels play pivotal role in 
several aspects of microglial activation [29], including pro-
liferation [30], cell shape transition, migration [31], NADPH 
oxidase—dependent respiratory burst [22] and cytokine 
release [32]. Finally, the role of Kv1.3. in the pathophysiol-
ogy of MS/EAE is demonstrated with Kv1.3 channel block-
ers which relieve the autoimmune neuroinflammation, by 
preserving the integrity of BBB [33], reducing activation of 
 TEM cells [34] and abolishing respiratory burst in activated 
microglia and subsequent deleterious effects of these cells 
on neuronal survival [23]. These findings make Kv1.3 valu-
able potential therapeutic target for immunosupression in 
MS and EAE [34].
It is well known that the Kv1.3 channels are fundamen-
tally involved in the regulation of the immune response of 
several immune cell types implicated in the pathophysiol-
ogy of MS/EAE [10] and currently, several selective Kv1.3. 
channel blockers are validated in the preclinical studies for 
their performance in MS [35]. Most of the basic research in 
EAE and clinical research in MS is focused on the under-
lying mechanism by which Kv1.3. channel blockers sup-
press infiltrated T cell activation and relieve autoimmune 
symptoms. However, little is known about localization and 
expression of Kv1.3 by resident glial cells in the spinal cord, 
both in physiological conditions and in EAE. Therefore, in 
the present study we have analyzed expression and cellu-
lar distribution of Kv1.3 in the lumbosacral spinal cord of 
Dark Agouti rats (DA) during EAE. We have demonstrated 
that besides infiltrated macrophages and reactive microglia, 
Kv1.3 channel protein is expressed by reactive astrocytes 
during the symptomatic phase of the disease. The role of 
Kv1.3 channels in function of fully developed reactive 
astrocytes was assessed in the subsequent in vitro study 
performed on C6 astrocytoma cell line in the presence of 
selective blocker of Kv1.3. channels agitoxin-2 (AgTx2). It 
was demonstrated that Kv1.3 channel blockade did not affect 
C6 morphology, but interfered with induction of proinflam-
matory genes in the cells.
Materials and Methods
Experimental Animals
Two-month old female rats of DA strain were used through-
out the experiments. Experimental procedures were 
approved by Ethical Committee for the Use of Laboratory 
Animals of Institute for Biological Research “Sinisa Stanko-
vic” (Belgrade, Serbia), in compliance with EEC Directive 
(2010/63/EU) on the protection of animals used for experi-
mental and other scientific purposes. Animals were housed 
(3–5/cage) under standard conditions (23 ± 2 °C, 50–60% 
relative humidity, 12 h/12 h light/dark cycle), with free 
access to food and water. During the period of paralysis, 
animals were given water by hand.
Induction of EAE and Assessment of Disease 
Severity
Animals were randomly divided into control (n = 10) and 
EAE group (n = 30). EAE was induced by subcutaneous 
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injection of the spinal cord homogenate (syngenic spinal 
cords homogenized in 50% w/v saline) mixed with an equal 
volume of complete Freund’s adjuvant supplemented with 
0.5 mg/ml Mycobacterium tuberculosis (CFA; Sigma, St. 
Louis, MO, USA).
All animals were weighed and examined daily, while EAE 
group was graded for neurological signs of EAE for 29 days 
post immunization (dpi). Two independent researchers 
unfamiliar with the experiment protocol and experimental 
groups examined the animals. Disease score was evaluated 
according to standard 0–5 EAE grading scale: 0—without 
symptoms; 1—atony of tail; 2—hind limb weakness; 3—
hind limb paralysis; 4—tetraplegic; 5—moribund state or 
death. Average disease score and weight were calculated 
for every time point. First signs of the disease appeared on 
7 dpi, which was designated as disease onset  (Eo). Peak of 
the disease occurred at 14 dpi  (Ep), after which the animals 
slowly recovered, with 29 dpi used as the end of disease  (Ee). 
At these time points animals were sacrificed and spinal cord 
tissue was used for analyses.
Tissue Preparation
Deep anesthesia was induced with Zoletil®50 (Virbac, 
France; 30 mg/kg i.p.), animals were perfused intracardi-
ally with ice cold saline solution after which the animals 
were decapitated. Age-matched animals that were not immu-
nized were used as controls. Spinal cords were isolated with 
hydraulic extrusion [36] and lumbar regions of the spinal 
cord were quickly dissected on ice.
Quantitative Real‑Time PCR
Excised lumbar segments of the spinal cords were placed 
in sterile tubes with RNAlater stabilization solution (Invit-
rogen, Carlsbad, CA, USA) and stored at − 80 °C until all 
groups were collected. In cell culture experiments, cells of 
C6 glioma cell line were treated for 4 h with AgTx2, a pore 
blocker of Kv1.3 channels, and IFN-γ and then harvested. 
Total RNA was extracted with TRIzol reagent (Invitrogen, 
Carlsbad, CA, USA) following standard procedure. Con-
centration of RNA was determined by measuring absorb-
ance at 260 nm, while purity of the sample was evaluated 
by the ratio of absorbance measurements at 260/280 nm and 
260/230 nm. From each sample 1 µg of RNA was transcribed 
to cDNA using High Capacity cDNA Reverse Transcription 
Kit (Applied Biosystems, Foster City, CA, USA). Quanti-
tative real-time PCR (qRT-PCR) analyses were performed 
using SYBR Green PCR master mix (Applied Biosystems, 
Foster City, CA, USA) and designated primers (Table 1, Inv-
itrogen, Carlsbad, CA, USA). Reactions were performed in 
the QuantStudio™ 3 Real-Time PCR System (Applied Bio-
systems, Foster City, CA, USA). Relative changes in gene 
expression were determined by comparing Ct values of the 
gene of interest to Ct values of internal control (GAPDH), 
using the  2−ΔCT method.
Western Blot
Isolated lumbar regions of spinal cords were pooled (three 
per group) for plasma membrane preparation, as previously 
described [37]. Briefly, tissue homogenization was per-
formed on ice in 5 mM Tris buffer, pH 7.4 that contains 
0.32 M sucrose, with subsequent centrifugation at 1000×g 
for 10 min, at 4 °C. The precipitate that contained residues 
of blood and cell nuclei was discarded and the supernatant 
was centrifuged in ultracentrifuge at 12,000×g for 30 min, 
at 4  °C. The resulting precipitate was resuspended and 
homogenized in 5 mM Tris, pH 7.4 with protease inhibitors 
(Roche, Penzberg, Germany). Isolated plasma membranes 
were stored at − 80 °C until all the groups were collected.
Protein concentration in all samples was determined with 
BCA protein assay kit (Pierce Biotechnology, Rockford, IL, 
USA), following manufacturer’s instructions. Equal amounts 
of protein (20 µg) were loaded onto 7.5% polyacrylamide 
gels and separated electrophoretically under reducing con-
ditions at 100–120 V. Resolved proteins were transferred 
to PVDF membranes (Roche, Penzberg, Germany) for 1 h, 
at 100 V. Unspecific binding was blocked with 5% bovine 
serum albumine (BSA, Sigma-Aldrich, Munich, Germany) 
in Tris buffered saline with 0.05% Tween 20 (TBST) 
(20 mM Tris, pH 7.6, 136mMNaCl, 0.1% Tween 20) for 1 h 
at room temperature (RT). The membranes were incubated 
with Kv1.3 primary antibody (Table 2) in TBST, overnight 
at 4 °C. On the next day, the blots were washed in TBST 
three times for 10 min and then incubated with appropriate 
HRP-conjugated secondary antibody (Table 2) for 2 h, at 
RT. Luminol (Sigma-Aldrich, Munich, Germany) was used 
Table 1  List of primers used for 
qRT-PCR Target gene Forward primer Reverse primer
GAPDH CAA CTC CCT CAA GAT TGT CAG CAA GGC ATG GAC TGT GGT CAT GA
KCNA3 GCT CTC CCG CCA TTC TAA G TCG TCT GCC TCA GCA AAG T
TNF-α CTC CCA GAA AAG CAA GCA AC CGA GCA GGA ATG AGA AGA GG
IL-6 CCG GAG AGG AGA CTT CAC AG ACA GTG CAT CAT CGC TGT TC
CCL2 CAG GTC TCT GTC ACG CTT CTG CTC CAG CCG ACT CAT TGG G
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to visualize protein bands and band intensity was determined 
with ImageQuant 5.2 software. Optical density of the tar-
get band was normalized to optical density of the β-actin 
band of the same lane, to exclude the effect of uneven pro-
tein loading. Results are expressed as mean optical density 
ratio ± SEM from three separate determinations.
Immunofluorescence Staining
For immunofluorescence studies isolated lumbar sections 
of the spinal cord were fixed in 4% paraformaldehyde in 
0.1 M phosphate buffer (PBS), pH 7.4 overnight at 4 °C 
and then cryoprotected in increasing solutions of sucrose 
(10–30% in 0.1 M PBS, pH 7.4). Afterward, the tissue was 
frozen in 2-methyl butane and stored at − 80 °C. Coronal 
sections (20 µm thick) were cut on cryotome and 5–6 con-
secutive sections were mounted on a glass slide. The slices 
were left to dry for 2 h at RT and were kept at − 20 °C until 
immunofluorescent staining. Before immunostaining the 
slides were first rinsed in PBS and then immersed in 0.25% 
Triton X-100 in PBS for 15 min. After washing the slides in 
PBS for 3 × 5 min, unspecific binding was blocked with 5% 
BSA (Sigma-Aldrich, Munich, Germany) in PBS for 1 h at 
RT. Incubation with primary antibody for Kv1.3 (Table 2) 
was done overnight at 4 °C. On the next day, the slides were 
washed for 3 × 5 min in PBS and then incubated with sec-
ondary anti-rabbit Alexa Fluor 555 fluorescent antibody 
(Table 2) for 2 h at RT. After washing in PBS, primary anti-
bodies for specific cell markers were used: glial fibrillary 
acidic protein (GFAP) and vimentin, as markers of astro-
cytes, ED1, marker of activated macrophages/microglia, 
and Iba1, marker of microglia. Incubation with these pri-
mary antibodies was also performed overnight, at 4 °C. After 
PBS wash, the slides were incubated with the appropriate 
secondary Alexa Fluor 488 antibodies. Nuclei were stained 
with Hoechst 33342 for 10 min at RT, and after thorough 
washing with PBS, sections were mounted with Mowiol 
(Calbiochem, Millipore, Germany). Immunohistochemis-
try was performed with appropriate controls, as suggested 
by Burry and Hewitt with coworkers [38, 39]. Appropriate 
negative control with blocking peptide for Kv1.3 (Alomone, 
Jerusalem, Israel) was done to ensure antibody specificity. 
Immunofluorescence was captured with Zeiss Axiovert 
fluorescent microscope (Zeiss, Jena, Germany), using ×40 
magnifications or ×63 magnification and Apotome system 
for obtaining optical sections.
Image Analysis and Quantification
Sections of the spinal cord labeled with Kv1.3/Iba1 and 
Kv1.3/GFAP were used for quantification of expression 
of this channel by microglia and astrocytes. Quantification 
was performed using ImageJ software package (National 
Institutes of Health, Bethesda, Maryland, USA), as previ-
ously described [40]. Briefly, sections from each group were 
divided into four quadrants—dorsal, ventral and right and 
left lateral, and two to four non-overlapping images of each 
quadrant were taken. Each image was examined for single 
labeled (Kv1.3, Iba1, GFAP) and double labeled (Kv1.3/
Iba1 and Kv1.3/GFAP) cells (for Iba1) or cellular processes 
(for GFAP). Identifying respective single channels was 
compared with merged images. The results are expressed 
as mean % of Kv1.3 expressing  Iba1+/GFAP+ of the total 
number of  Iba1+/GFAP+ cells from sections of three animals 
per group ± SEM.
Cell Culture and Treatment
The C6 astrocytoma cell line is a widely used model for 
analysis of astrocytes [41, 42]. The C6 cells express many 
astrocyte specific markers, including GFAP and S-100B pro-
tein [43, 44]. The cells were cultured under standard condi-
tions (37 °C, 95% air/5%  CO2), in RPMI 1640 medium (GE 
Healthcare Life Sciences, Freiburg, Germany) supplemented 
with 10% heat-inactivated fetal bovine serum (FBS, Gibco, 
Waltham, MA, USA) and 1% penicillin/streptomycin (Invit-
rogen, Carlsbad, CA, USA). Upon reaching 80% confluence, 
cells were detached with 0.1% trypsin–EDTA and seeded 
into appropriate sterile dishes and incubated overnight. Cells 
were treated with 5 nM AgTx2 (Sigma-Aldrich, Munich, 
Germany) 30 min prior to stimulation with 500 U/ml IFN-γ 
(R&D Systems, Minneapolis, USA) for 4 h for qRT-PCR and 
24 h for other analyses. For qRT-PCR analysis, 2.5 × 105 C6 
cells were seeded in 6-well plates, treated as described and 
then collected with Trizol reagent. Further isolation of RNA, 
cDNA synthesis and qRT-PCR analysis was performed as 
described in PCR section of “Material and Methods”.
Analysis of Cell Viability and Cell Morphology
Screening of C6 cell line viability and morphology was per-
formed with xCELLigence Real-Time Cell Analyzer Single 
Plate instrument (RTCA SP, ACEA Biosciences, San Diego, 
Table 2  List of primary and secondary antibodies used for immuno-
fluorescence (IF) and western blot (WB)
Antigen Source Dilution Company
Kv1.3 Rabbit 1:200 IF
1:500 WB
Alomone Labs, APC-004
β-Actin Mouse 1:5000 WB Sigma-Aldrich, A2228
ED1 Mouse 1:100 IF Abcam ab31630
Iba1 Goat 1:400 IF Abcam ab5076
GFAP Mouse 1:500 IF UC Davis/NIH Neuro-
Mab Facility (73–240)
Vimentin Mouse 1:200 IF Dako, M0725
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CA, USA). RTCA measures cell status in real time by analyz-
ing impedance, a value created by interference of cells with 
microelectrodes on the bottom of E-plate, a special 96-well 
plate in which cells are grown that connects to RTCA instru-
ment. The impedance is expressed as a Cell Index value that 
correlates with number, viability, adherence and morphology 
of cells. The C6 cells were seeded in E-plate (1 × 104), left to 
adhere overnight, pretreated with 5 nM AgTx2 and stimulated 
with 500 U/ml IFN-γ for 24 h, as described. During the whole 
experiment Cell Index was recorded (in 5 min intervals) and 
the results are normalized to time of treatment with IFN-γ 
and expressed as Normalized Cell Index. Cell index value of 
RPMI 1640 medium was the background measurement that 
was subtracted from all the results.
To analyze cell morphology in further detail F-actin was 
stained with Alexa Fluor 555 phalloidin (Invitrogen, Carls-
bad, CA, USA). C6 cells were seeded on glass cover-slips 
(Ø25 mm) at the density of 6 × 104 and put in 35 mm dishes 
(Sarstedt, Newton, NC, USA). Treatment with IFN-γ and 
AgTx2 lasted for 24 h after which the cells were fixed with 
4% paraformaldehyde for 20 min at 4 °C. After a wash with 
PBS, glass coverslips were put in 0.25% Triton X-100 (Sigma-
Aldrich, Munich, Germany) to permeabilize the cell mem-
brane and allow for staining of intracellular F-actin (dilution 
of 1:50 in PBS) for 30 min at RT. Hoechst 33342 (5 µg/ml, 
Life Technologies, Invitrogen, Carlsbad, CA, USA) was used 
for 5 min at RT to stain cell nuclei. Coverslips were mounted 
with Mowiol (Calbiochem, Darmstadt, Germany) and images 
acquired with confocal laser scanning microscope (LSM 510, 
Carl Zeiss GmbH, Jena, Germany) using Ar Multi-line (457, 
478, 488, and 514 nm) and HeNe (543 and 633 nm) lasers, 
and 63 × DIC oil and 100 × DIC oil objectives. Images were 
analyzed using AxioVisionRel 4.9.1 software (Zeiss, Jena, 
Germany). Mean cell surface area was determined in ten areas 
(146 × 146 µm) per cover-slip, with two cover-slips per group, 
in three independent sets of experiments.
Data Analysis
Results are expressed as mean values ± SEM, except for 
disease score assessment where the results are presented 
as mean ± standard deviation. Statistical significance was 
analyzed with GraphPad Prism software. The results were 
analyzed with One-Way ANOVA and Bonferroni post-hoc 
test. Values of p < 0.05 were considered to be statistically 
significant.
Results
Time‑Course Changes of Clinical Signs During EAE
EAE was induced in immunized animals with 100% inci-
dence and monophasic course. Time-course changes in 
disease score and animal weight are shown in Fig. 1. First 
clinical signs appeared at 7 dpi, reached a maximum at 
14 dpi, after which the animals slowly recovered until 
29 dpi. These time points were taken as onset  (Eo), peak 
 (Ep) and end of disease  (Ee). Development of clinical signs 
was concurrent with body weight loss, which was most 
pronounced at  Ep.
Kv1.3 Is Upregulated at the Peak of EAE
Expression of Kv1.3 in the lumbosacral region of the spinal 
cord during EAE was evaluated with qRT-PCR and Western 
blot (Fig. 2). The expression levels of Kv1.3 corresponded 
to the rise in clinical manifestations of EAE. Almost two-
fold increase in Kv1.3-mRNA (KCNA3, Fig. 2a) and about 
four-fold increase in the protein abundance (Fig. 2b) were 
demonstrated at the peak of illness. To investigate which 
cells were responsible for the observed Kv1.3 upregulation, 
in the next set of experiments we performed double immu-
nofluorescence labeling for Kv1.3 and cell-specific markers.
Fig. 1  Assessment of disease severity and clinical score. EAE was 
induced by subcutaneous injection of spinal cord homogenate mixed 
with an equal volume of complete Freund’s adjuvant with 0.5 mg/ml 
Mycobacterium tuberculosis. Animals were scored daily according 
to standard 0–5 EAE grading scale (red line): 0—without symptoms; 
1—atony of tail; 2—hind limb weakness; 3—hind limb paralysis; 4—
tetraplegic; 5—moribund state or death. Average disease score and 
body weight were calculated for every time point. Progress of EAE 
was associated with body weight loss, which was most pronounced at 
the peak of disease (black line). EAE animals were sacrificed at the 
onset (D7), peak (D14) and end (D29) of disease. Data are expressed 
as the mean clinical score ± SEM (10 rats per group). (Color figure 
online)
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Expression of Kv1.3 Is Upregulated on Activated 
Microglia and Macrophages During the Progression 
of EAE
Microglial expression of Kv1.3 was assessed by double 
immunofluorescence labeling of Kv1.3 with microglial 
marker Iba1 (Fig. 3). At control sections, rare  Iba1+ cells 
had small cell bodies and numerous ramified processes and 
did not express Kv1.3 (arrowheads, Fig. 3a–c, m). From the 
onset to the peak of disease activation of microglia evolved, 
which was reflected in increasing number of  Iba1+ cells and 
a noticeable change in the morphology, with enlarged 
cell bodies and processes that became fewer and thicker 
(Fig. 3d–i). At  Eo and  Ep 90% of Iba1 positive microglial 
cells expressed Kv1.3 (arrows, Fig. 3d–f, g–i, m). Highest 
number of these Kv1.3+  Iba1+ cells was found in inflamma-
tory infiltrates at the peak of disease (Fig. 3g–i). At the end 
of disease, percentage of Kv1.3 expressing microglial cells 
was reduced to 65% of total  Iba1+ cells (arrows, Fig. 3j–l, 
m). Expression of Kv1.3 at  Ep and  Ee was also noticed on 
cells with elongated processes that resembled astrocytes 
(arrowheads, Fig. 3g–i, j–l).
In control sections  ED1+ cells were not observed, how-
ever at onset and peak of disease many  ED1+ cells expressed 
Kv1.3 (Fig. 4). At  Ee amoeboid  ED1+ cells were largely 
devoid of Kv1.3, implying that Kv1.3 expression depends 
on the functional status of these cells.
Kv1.3 is Expressed on Reactive Astrocytes During 
the Progression of EAE
Subsequent double immunofluorescence labeling combining 
Kv1.3 and astrocyte markers GFAP and vimentin revealed 
that activated astrocytes abundantly expressed the channel 
(Figs. 5, 6). In control sections fibrous astrocytes with thin 
processes positive for GFAP and vimentin, did not express 
Kv1.3 (Figs. 5a–c, m, 6a–c). During the progression of 
EAE,  GFAP+ and  vimentin+ astrocytes had hypertrophied 
cell bodies with thick processes. At Eo the majority of 
astrocytes were not Kv1.3+ (Figs. 5d–f, 6d–f), with only 
10% of  GFAP+ astrocytes expressing Kv1.3 (Fig. 5m). At 
 Ep and  Ee, bulk of robustly labeled  GFAP+ and  vimentin+ 
fibrous elements co-expressed Kv1.3 (arrows, Figs. 5g–l, 
6g–l). Subsequent image analysis showed that 61 and 67% 
of  GFAP+ astrocytes expressed Kv1.3 at  Ep and  Ee, respec-
tively (Fig. 5m). These results indicate that Kv1.3 plays a 
role in astrocytic pathology during the course of EAE and 
that its expression on reactive astrocytes may contribute to 
the overall upregulation of the channel protein at the peak 
of disease.
Blockade of Kv1.3 Does Not Prevent IFN‑γ Induced 
Alterations in C6 Cell Morphology
The role of Kv1.3 in astrocyte function was investigated 
in C6 rat astrocytoma cell line, activated with IFN-γ [45, 
46], in the absence and presence of selective Kv1.3 chan-
nel blocker AgTx2. Changes in the cell viability and mor-
phology were quantified by noninvasive electrical imped-
ance monitoring with xCelligence® RTCA DP instrument 
(Fig. 7a). The resulting cell index gradually increased in 
Fig. 2  Expression of Kv1.3 in lumbar part of rat spinal cords during 
EAE. (a) Expression of KCNA3 mRNA was assessed by qRT-PCR 
in control (C) and animals with EAE at the onset  (Eo), peak  (Ep) 
and end  (Ee) of disease. GAPDH was used as endogenous control. 
Results are expressed as % of change compared to values in control 
animals. (b) Protein levels of Kv1.3 were assessed with quantitative 
western blot analysis, with β-actin used as loading control. Results 
are expressed as mean Kv1.3 protein abundance ± SEM. Significance 
level inside the graph: *P < 0.05 compared to control
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all groups during the 24 h the cells were monitored. Group 
treated with IFN-γ had cell index values that were higher 
compared to control, pointing to changes in morphology as 
a consequence of activation. Cells pretreated with AgTx2 
and then stimulated with IFN-γ had lower cell index val-
ues compared to IFN-γ alone, however this difference was 
not statistically significant. The role of Kv1.3 in C6 cell 
morphology was further studied by analyzing the microfila-
ment organization in the cells activated with IFN-γ, in the 
absence or presence of AgTx2 (Fig. 7b). Untreated cells had 
polygonal shape with scattered stress fibers oriented in dif-
ferent directions. Following treatment with IFN-γ, the cells 
surface area considerably increased (Fig. 7c), together with 
rearrangement of the microfilaments. The polymerization 
of F-actin fibers to stress fibers increased and these IFN-γ 
induced changes in cell morphology were not prevented with 
AgTx2 pretreatment.
Blockade of Kv1.3 Suppresses Expression 
of Proinflammatory Mediators in C6 Cells
We further tested whether the blockade of Kv1.3 interferes 
with the induction of proinflammatory genes in C6 cells 
stimulated with IFN-γ. As presented in Fig. 8, the abundance 
of transcripts encoding for TNF-α, IL-6 and CCL2 signifi-
cantly increased up to 190, 250 and 275% respectively, in C6 
cells treated with IFN-γ in comparison to non-treated cells, 
whereas the mRNA abundances were markedly reduced by 
Kv1.3 channel blocker. Specifically, AgTx2 reversed the 
cytokine-induced increase in TNF-α and considerably sup-
pressed CCL2, but did not interfere with production of IL-6. 
These results suggest that Kv1.3-mediated  K+ currents and 
the resulting membrane repolarization may have a role in the 
induction of proinflammatory genes by activated astrocytes 
in vitro.
Discussion
In the present study we evaluated the expression pattern of 
Kv1.3 on gene and protein level in spinal cords of animals 
during EAE. Cell specific profiling was performed to assess 
cell types expressing Kv1.3 at different time points in the 
disease progression. We have shown that in addition to the 
microglial/macrophages expression, reactive astrocytes in 
rat spinal cord express Kv1.3 at the peak and end of dis-
ease. Inhibition of Kv1.3 in activated astrocytes in vitro 
suppressed gene expression of proinflammatory markers, 
associating Kv1.3 with proinflammatory role of astrocytes.
Kv1.3 has been in the focus of MS research in recent 
years, predominantly for its important role in  TEM cells 
that are main mediators of autoimmunity. Terminally dif-
ferentiated autoantigen specific  TEM cells with  CCR7− and 
 CD45RA− phenotype upregulate Kv1.3 and migrate to 
inflamed tissues where they perform effector functions and 
contribute to disease progression [13]. Kv1.3 is involved 
in T cell activation by preventing membrane depolarization 
and keeping the driving force for entry of  Ca2+ that activates 
signaling cascades leading to cytokine production and pro-
liferation of T cells. These processes are enabled with efflux 
of  K+ through Kv1.3 [12]. Administering Kv1.3 antagonist 
in vivo alleviated symptoms of EAE [33, 47–51] and was 
shown to maintain integrity of BBB [33]. Additionally, 
Kv1.3 knockout mice showed lower incidence and severity 
of EAE compared to wild type animals [52].
Although the role of Kv1.3 in MS has been studied, 
changes in its cellular and temporal expression have not been 
investigated in the spinal cord in animal models of MS, such 
as EAE. We used the EAE model in DA rats, previously 
reported to be highly susceptible in developing the disease, 
although the changes are only detectable in the spinal cord. 
Our results show that Kv1.3 is expressed at gene but scarcely 
at protein level in spinal cords of healthy control animals, as 
was determined with qRT-PCR and western blotting/double 
immunofluorescence studies, respectively. Our results are 
in agreement with a previous study that identified KCNA3 
mRNA but failed to detect protein expression in the spinal 
cords of healthy Wistar rats [53]. In our study, several fold 
upregulation of Kv1.3 was detected at the peak of disease on 
both protein and mRNA level. With the resolution of EAE, 
expression of Kv1.3 subsided. Double immunofluorescence 
studies demonstrated how these changes are correlated to its 
expression pattern on different cell types in the spinal cord 
of EAE animals.
As professional APCs, infiltrated macrophages play 
a key role in EAE, producing an array of cytokines and 
influencing T cell activation [2]. Kv1.3 activity influences 
the degree of macrophage activation and increase in Kv1.3 
expression in activated macrophages was determined in 
cell culture [19, 54] and in MS brain inflammatory infil-
trates [15]. In our study we showed disease phase depend-
ent changes in Kv1.3 expression in the inflammatory infil-
trates with double staining for ED1, marker of activated 
microglia and macrophages. At the onset and peak of the 
disease, expression of Kv1.3 was observed in a subset of 
 ED1+ cells. However, at the end of disease no  ED1+ cells 
expressed Kv1.3, suggesting that this channel has a role 
in macrophages for a limited time frame. This role could 
be in relation to formation of foam cells. It was previ-
ously shown that Kv1.3 is involved in cholesterol metabo-
lism and participates in differentiation of macrophages to 
foam cells [55]. Foamy macrophages ingest myelin and 
are characteristic for demyelinating lesions in MS/EAE, 
as we have shown previously [56]. They appear to have a 
complex role in disease progression as they express both 
pro- and anti-inflammatory markers [57, 58]. Considering 
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that activation of Kv1.3 in macrophages has been linked 
to their proliferation and NO production [18], inhibiting 
Kv1.3 at the onset and peak of EAE, corresponding to 
symptomatic phase of MS, could be beneficial for disease 
progression.
Furthermore, we showed an increase in Kv1.3 expression 
in microglia in spinal cords of EAE animals. Specifically, 
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we demonstrated that at the onset and peak of the dis-
ease 90% of  Iba1+ cells expressed Kv1.3. This percentage 
decreased to 65% by the end of disease, and the number of 
activated microglia subsided. We can conclude that Kv1.3 
has a role in activated microglia throughout the disease. Role 
of Kv1.3 in pro-inflammatory activation of microglia has 
been described in vitro [22, 23, 59]. Recently, Nguyen et al. 
showed that microglia with pro-inflammatory phenotype had 
higher Kv1.3 currents concluding that inhibiting Kv1.3 has 
a selective effect on pro-inflammatory subtype of microglia 
[60]. In view of previous studies, we confirm the expression 
of Kv1.3 in microglia in our EAE model and we propose 
that inhibiting this channel in microglia would be valuable 
throughout the disease.
Considering that astrocytes have multiple functions in 
the pathophysiology of MS and directly contribute to neu-
roinflammation [8, 61], we further investigated whether 
Kv1.3 is expressed on astrocytes in EAE model. As in other 
neurodegenerative diseases, during the course of MS and 
EAE astrocytes become activated, proliferate and change 
their morphology. Their cell bodies become bigger and 
processes thicker and longer, eventually forming the glial 
scar [62]. Their reaction depends on the proximity to the 
demyelinating lesions, with astrocytes near the lesion site 
exhibiting a stronger response. Even though astrocytes 
have many deleterious roles in MS they also show some 
protective characteristics and help in promoting remyelina-
tion [9]. In this study we find for the first time that Kv1.3 
is expressed on reactive astrocytes around demyelination 
sites in spinal cords of EAE animals. This phenomenon was 
most pronounced at the peak and end of disease where 60% 
of astrocytes expressed Kv1.3. To corroborate the expres-
sion of Kv1.3 on activated astrocytes we performed double 
immunofluorescence analyses with two astrocytic markers, 
GFAP and vimentin. GFAP is the typical marker of mature 
astrocytes and vimentin is characteristic intermediate fila-
ment of immature astrocytes, however both are upregulated 
in activated astrocytes in different neurodegenerative dis-
eases [63, 64]. Vimentin has been shown to be increased in 
a subpopulation of reactive astrocytes as the inflammation 
subsides in EAE [65]. In our model we found that expression 
of Kv1.3 coincided with both of these markers, suggesting 
that this channel is expressed on different subpopulations 
of astrocytes. Although our immunofluorescence analyses 
show expression of Kv1.3 on astrocytes and microglia at 
the end of disease, results from qRT-PCR and western blot 
analyses demonstrate that highest increase of both gene 
and protein expression is at the peak of disease. We assume 
this is because the highest number of inflammatory cells 
occurs at the peak of disease, and a large subset of these cells 
express Kv1.3, including T cells that were not the subject of 
this study but have been studied previously [12, 13]. Kv1.3 
was previously detected in astrocytes in C6 cells in culture 
[66], in mixed glial cultures and astrocytes in the corpus 
callosum of animals that suffered traumatic brain injury, 
where its expression was moderate compared to microglia 
[67]. Bearing in mind that astrocytes have dual roles in MS 
and EAE we examined how blockade of Kv1.3 affects their 
activation in vitro. Blocking Kv1.3 did not affect the cell size 
of activated astrocytes; however it suppressed expression 
of proinflammatory markers TNF-α and CCL2. One of the 
most detrimental astrocytic processes in MS and EAE is the 
production of proinflammatory cytokines and chemokines. 
Fig. 3  Double immunofluorescence labeling for Kv1.3 and Iba1 in 
the lumbar part of spinal cords of control and EAE animals. Kv1.3 
(red fluorescence) was not detected in control animals (a). Arrow-
heads denote  Iba1+ cells (green fluorescence, b, c) with quiescent 
morphology. Expression of Kv1.3 was detected at a majority of  Iba1+ 
cells at  Eo (disease grade 1, arrows, d–f). At  Ep (disease grade 3.5) 
expression of Kv1.3 was massive in inflammatory infiltrates and 
coincided with Iba1 (arrows, g–i), but was also found on cells that 
resembled astrocytes in morphology (arrowheads, g–i). At  Ee (disease 
grade 0.5)  Iba1+ cells expressed Kv1.3 (arrows, j–l), although to a 
lesser extent and Kv1.3 was massively found on cells that resembled 
astrocytes. Nuclei of all cells were visualized with DAPI (blue) stain-
ing. The graph denotes changes in % of  Iba1+ cells that expressed 
Kv1.3 throughout the disease (m). Significance level inside the graph: 
*P < 0.05 compared to control. Magnification: ×63, scale bar: 20 µm. 
(Color figure online)
◂
Fig. 4  Double immunofluorescence labeling for Kv1.3 and ED1 in 
the lumbar part of spinal cords of control and EAE animals. Neither 
Kv1.3 (red fluorescence) nor ED1, a marker of activated microglia 
and macrophages (green fluorescence) was found in control animals. 
At onset (disease grade 1) and peak (disease grade 3.5) of disease 
many  ED1+ cells expressed Kv1.3, while this channel was not found 
on activated microglia and macrophages at the end of disease (disease 
grade 0.5). Nuclei of all cells were visualized with DAPI (blue) stain-
ing. Magnification; ×40, scale bar: 200 µm. (Color figure online)
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Fig. 5  Double immunofluorescence labeling for Kv1.3 and GFAP in 
lumbar part of spinal cords of control and EAE animals. Expression 
of Kv1.3 (red fluorescence) was not detected in  GFAP+ astrocytes 
(green fluorescence) in control animals (a–c). At  Eo (disease grade 1) 
a small subset of reactive astrocytes expressed Kv1.3 (d–f), while at 
 Ep (disease grade 3, arrows, g–i) and  Ee (disease grade 0.5, arrows, 
j–l) the number of Kv1.3+/GFAP+ increased. Nuclei of all cells were 
visualized with DAPI (blue) staining. The graph denotes changes in 
% of  GFAP+ cells that expressed Kv1.3 throughout the disease (m). 
Significance level inside the graph: *P < 0.05 compared to control. 
Magnification: ×63, scale bar: 20 µm. (Color figure online)
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Increase in TNF-α was detected in cerebrospinal fluid of 
MS patients [68] and it was shown that TNF-α levels are 
in direct proportion to extent of demyelination in MS [69]. 
TNF-α from astrocytes suppresses expression of glutamate 
transporters, undermining astrocytic glutamate intake and 
thus promoting neuronal degeneration [70]. Similarly, 
chemokine CCL2 is increased in astrocytes in MS lesions 
and EAE, and has an integral part in mobilizing immune 
cells to CNS [71, 72]. Furthermore,  CCL2−/− mice are pro-
tected from EAE and it has been suggested that CCL2 has 
an important function at the onset of EAE [73]. Considering 
that inhibition of Kv1.3 leads to a decrease in expression 
of these proinflammatory markers we can conclude that 
Kv1.3 has a role in proinflammatory actions of astrocytes 
in neuroinflammation.
Collectively, our data extend the existing knowledge on 
the Kv1.3 role in EAE by showing specific expression pro-
file of Kv1.3 in spinal cords of EAE animals and pointing 
to a proinflammatory role of this channel in activated astro-
cytes that has not been described up to now. Kv1.3 expres-
sion was upregulated on gene and protein level during EAE 
and this upregulation correlated with clinical disease score. 
We found that this was a consequence of Kv1.3 upregulation 
Fig. 6  Double immunofluorescence labeling for Kv1.3 and vimentin 
in lumbar part of spinal cords of control and EAE animals. Expres-
sion of Kv1.3 (red fluorescence) was not detected in  vimentin+ 
astrocytes (green fluorescence) in control animals (a–c). At  Eo (dis-
ease grade 1) some  vimentin+ astrocytes expressed Kv1.3 (arrows, 
d–f). At  Ep (disease grade 3.5, arrows, g–i) and  Ee (disease grade 0.5, 
arrows j–l) Kv1.3 was detected on many  vimentin+ astrocytes. Nuclei 
of all cells were visualized with DAPI (blue) staining. Magnification: 
×63, scale bar: 20 µm. (Color figure online)
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in cells that contribute to neuroinflammation, namely acti-
vated macrophages, microglia and astrocytes. Our results 
confirm that Kv1.3 may be an interesting therapeutic target 
for MS, adding astrocytes to the list of cells whose activation 
would be suppressed by inhibiting Kv1.3 in inflammatory 
conditions.
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Fig. 7  Evaluation of activation of C6 cells in vitro. (a) C6 cells were 
treated with AgTx2, stimulated with IFN-γ and their viability and 
morphology were assessed with RTCA instrument. Representative 
graph shows status of cells in control medium (red line), medium 
with 500  U/ml IFN-γ (green line) and cells pretreated with 5  nM 
AgTx2 and after 30 min stimulated with IFN-γ (blue line) for 24 h. 
(b) Morphology of C6 cells was determined with Phalloidin/Hoe-
chst fluorescent staining (red/blue). (c) Cell surface was quantified 
using AxioVisionRel 4.6 software. Bars present mean surface areas 
(± SEM) from three separate determinations. Significance level inside 
the graph: *P < 0.05 compared to control. Scale bar: 20  µm. (Color 
figure online)
Fig. 8  Blocking Kv1.3 in activated C6 astrocytes with AgTx2 sup-
presses mRNA expression of proinflammatory markers. Levels of 
TNF-α, IL-6, and CCL2 mRNA were assessed with qRT-PCR in C6 
cells pretreated with 5  nM AgTx2 and then activated with 500  U/
ml IFN-γ for 4 h. GAPDH was used as endogenous control. Results 
are expressed as % of change compared to values in control cells. 
Graph shows mean values ± SEM. Significance level inside the graph: 
*P < 0.05 compared to control, #P < 0.05 compared to IFN-γ activated 
cells
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